Publications
Detailed Information
Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8+ T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeon, Yun-Hui | - |
dc.contributor.author | Lee, Namhee | - |
dc.contributor.author | Yoo, Jiyoon | - |
dc.contributor.author | Won, Solchan | - |
dc.contributor.author | Shin, Suk-Kyung | - |
dc.contributor.author | Kim, Kyu-Hwan | - |
dc.contributor.author | Park, Jun-Gyu | - |
dc.contributor.author | Kim, Min-Gang | - |
dc.contributor.author | Kim, Hang-Rae | - |
dc.contributor.author | Oh, Keunhee | - |
dc.contributor.author | Lee, Dong-Sup | - |
dc.date.accessioned | 2024-05-16T01:27:06Z | - |
dc.date.available | 2024-05-16T01:27:06Z | - |
dc.date.created | 2022-05-02 | - |
dc.date.created | 2022-05-02 | - |
dc.date.created | 2022-05-02 | - |
dc.date.created | 2022-05-02 | - |
dc.date.issued | 2022-04 | - |
dc.identifier.citation | Biomedicines, Vol.10 No.4, p. 805 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | https://hdl.handle.net/10371/202530 | - |
dc.description.abstract | © 2022 by the authors. Licensee MDPI, Basel, Switzerland.Oncolytic virotherapy has garnered attention as an antigen-agnostic therapeutic cancer vaccine that induces cancer-specific T cell responses without additional antigen loading. As anticancer immune responses are compromised by a lack of antigenicity and chronic immunosuppressive microenvironments, an effective immuno-oncology modality that converts cold tumors into hot tumors is crucial. To evaluate the immune-activating characteristics of oncolytic vaccinia virus (VACV; JX-594, pexastimogene devacirepvec), diverse murine syngeneic cancer models with different tissue types and immune microenvironments were used. Intratumorally administered mJX-594, a murine variant of JX-594, potently increased CD8+ T cells, including antigen-specific cancer CD8+ T cells, and decreased immunosuppressive cells irrespective of tissue type or therapeutic efficacy. Remodeling of tumors into inflamed ones by mJX-594 led to a response to combined anti-PD-1 treatment, but not to mJX-594 or anti-PD-1 monotherapy. mJX-594 treatment increased T cell factor 1-positive stem-like T cells among cancer-specific CD8+ T cells, and anti-PD-1 combination treatment further increased proliferation of these cells, which was important for therapeutic efficacy. The presence of functional cancer-specific CD8+ T cells in the spleen and bone marrow for an extended period, which proliferated upon encountering cancer antigen-loaded splenic dendritic cells, further indicated that long-term durable anticancer immunity was elicited by oncolytic VACV. | - |
dc.language | 영어 | - |
dc.publisher | MDPI AG | - |
dc.title | Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8+ T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/biomedicines10040805 | - |
dc.citation.journaltitle | Biomedicines | - |
dc.identifier.wosid | 000786328800001 | - |
dc.identifier.scopusid | 2-s2.0-85128337874 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 805 | - |
dc.citation.volume | 10 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Hang-Rae | - |
dc.contributor.affiliatedAuthor | Lee, Dong-Sup | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RESIDENT | - |
dc.subject.keywordPlus | SUBSETS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | cancer antigen-specific T cells | - |
dc.subject.keywordAuthor | immune checkpoint blockade | - |
dc.subject.keywordAuthor | lymphoid organs | - |
dc.subject.keywordAuthor | oncolytic vaccinia virus | - |
dc.subject.keywordAuthor | stem-like CD8+ T cells | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.